Effect of Oral Semaglutide Versus Comparators on Multiple Cardiometabolic Risk Factor Control in Adults With Type 2 Diabetes

<p dir="ltr">Type 2 diabetes is associated with multimorbidity, microvascular and<br>macrovascular complications, and increased mortality (1). A holistic approach to<br>treatment with multifactorial risk-reduction strategies is recommended to improve long-<br>term diabetes outcomes (2). This post hoc analysis of the PIONEER 1–8 (excluding<br>PIONEER 6) trials evaluated the efficacy of oral semaglutide versus placebo or active<br>comparators in reducing four cardiometabolic risk factors. [Opening paragraph]</p>